Search results
Showing results for
An unconventional clinical trial design might have advantages over classical trials for testing treatments for Ebola virus disease (EVD), suggests a study published this week in PLOS Medicine. The work of an international team led by John Whitehead of Lancaster University, UK and Ben Cooper (Oxford University, UK, and Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand) provides much-needed data to inform a debate on the scientific and ethical justification for non-randomized EVD trials that has taken place in the editorial pages of a number of medical journals in past months.
Christiane Dolecek
MD PHD FRCP Christiane Dolecek - Professor of Global Health
Louise Thwaites
BSc MBBS MRCP MD DMSMed MLCOM Louise Thwaites - Professor of Experimental Critical Care
Phaik Yeong Cheah
Phaik Yeong Cheah - Professor of Global Health
Evelyne Kestelyn
Evelyne Kestelyn - Head of the Clinical Trials Unit
Bridget Wills
Bridget Wills - Professor of Tropical Medicine
Paul Newton
Paul Newton - Professor of Tropical Medicine
Wirichada Pan-ngum
Wirichada Pan-ngum - Associate Professor
Direk Limmathurotsakul
Direk Limmathurotsakul - Professor of Infectious Disease Epidemiology
Richard Hoglund
Richard Hoglund - Head of Pharmacometrics
Mehul Dhorda
Mehul Dhorda - DeTACT-Africa Coordinator / Head of Specimen Management Laboratory